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(63.4%). Five studies were related to digestive cancers and other included peptic 
diseases, hernias and other. ConClusions: There was a considerable increase in 
publications of economic evaluations in Gastroenterology in Brazil, being mostly 
studies of drugs for treatment of viral hepatitis. The high cost of these treatments 
and increased of lawsuits seem to account for this increase.
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EstImatInG thE Cost of LIvEr transPLantatIon In PatIEnts DIaGnosED 
WIth ChronIC hEPatItIs C anD B In thE Uk
Singh J., Longworth L.
Brunel University, Uxbridge, UK
objeCtives: Liver transplantation is an effective treatment option for end-stage 
liver disease and acute liver failure, including patients with hepatitis C (HCV) and 
hepatitis B (HBV). Recent health technology assessments of treatments for HCV 
and HBV have relied on data from a large cohort study of transplanted patients to 
inform estimates of costs of liver tranplantations; however this was conducted in 
the 1990s. The overall aim of this study was to estimate the current cost of liver 
transplant for patients with HCV and HBV in the UK. Methods: Historical sum-
mary data from the original cohort study were updated to reflect current unit costs 
and key changes in clinical practice. Semi-structured interviews were conducted 
with experts and a computer-based user-interface was developed to elicit estimates 
of key resource use items. Uncertainty in the experts’ estimates was captured by 
eliciting probability distributions for each item from each expert. Updated unit costs 
were obtained from national sources. Data were analysed by phase of the transplant 
procedure. Results: The expert elicitation exercise included two hepatologists, 
three transplant surgeons and one liver transplant coordinator. Few patients with 
HBV are now being transplanted due to improvements in anti-viral treatments. 
Mean total costs for patients with HCV were £18,055 pre-transplantation, £64,452 
during the transplant phase and £36,009 in two years post-transplant. The average 
cost per transplanted patient with HCV from assessment to two years post-trans-
plant is £111,810. ConClusions: There have been some significant changes in 
clinical practice since the original study such as change in standard immunosup-
pressant therapy, more patients with co-morbidities being placed on the transplant 
waiting list, increased use of sub-optimal organs and reluctance to re-transplant 
patients with graft failure and recurrence of HCV.
GastroIntEstInaL DIsorDErs – Patient-reported outcomes & Patient  
Preference studies
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aDhErEnCE ratEs for PEGIntErfEron + rIBavIrIn ComParED WIth 
tELaPrEvIr + PEGIntErfEron + rIBavIrIn In mEDICaID anD CommErCIaL 
PatIEnts trEatED for ChronIC hEPatItIs C
Samp J.C., Walker D., Manthena S., Juday T.
AbbVie, North Chicago, IL, USA
objeCtives: Prior to approval of telaprevir (TPV), the treatment for chronic hepatitis 
C virus (HCV) included peginterferon (P) weekly injections and ribavirin (R) orally 
twice daily. In 2011, TPV was approved for coadministration with P+R during the 
first 12 weeks. Though TPV improved viral clearance, it also increased the treat-
ment complexity by 2 pills given 3 times a day. The impact of increased regimen 
complexity on adherence is not well understood. This study compared treatment 
adherence over 24 weeks in HCV patients treated with TPV+PR compared to those 
on PR. Methods: Large US commercial and Medicaid health insurance claims 
databases were used to identify HCV patients initiating treatment with PR (pre-TPV 
[2007 to 2009]) or TPV+PR (post-TPV [2011 to 2013]). The index date was the date of 
HCV treatment initiation. Adherence was measured by medication possession ratio 
for all patients at 4 week intervals thru 24 weeks. Regression analyses adjusted for 
age, sex, comorbidities, liver disease severity, and pill count prior to HCV treat-
ment. Results: The study included 7,601 and 1,487 treated HCV patients in the 
commercial and Medicaid databases. Unadjusted and adjusted adherence was high 
for both cohorts throughout the study period (> 88% for Medicaid and > 82% for the 
commercial at 24 weeks). Adherence was not significantly different between the 
PR and T+PR cohorts at any time point in the Medicaid patients (88.9% [TPV+PR] 
and 90.5% [PR] at 24 weeks). Adherence was also similar between the cohorts in the 
commercial patients (82.7% [TPV+PR] and 83.2% [PR] at 24 weeks) but was statisti-
cally different at weeks 8 and 12, though not clinically meaningful. Age was the 
only factor consistently associated with adherence. ConClusions: Among HCV 
patients, adherence rates were high and were similar between the cohorts, despite 
the higher daily pill count for patients on TPV+PR.
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objeCtives: To estimate the utility scores for diarrheal children aged under 5 
years and their caregivers and to identify the influencing factors which affected 
on these. Methods: Hospitalized diarrheal children aged between 2 months and 
5 years and their caregivers at were recruited in this cross-sectional study at three 
hospitals in Phetchabun province. The EQ-5D instrument was used to collect the 
quality of life (QoL) data at the first date of admission. Quality of life of diarrheal 
children was measured as proxy report from caregiver while QoL of caregiver was 
measured as self-report. The raw data was converted to utility values using the Thai 
algorithm. The clinical severity of diarrheal children was rated using the Vesikari 
clinical severity scoring system. Stepwise multivariate linear regression was applied 
to explore the impact of the various factors on the utility value of children and 
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objeCtives: To conduct a cost-utility analysis of sofosbuvir for genotype 2 
chronic hepatitis C virus (HCV) infection in Japan. Methods: The Markov-model, 
“Sofosbuvir cost-effectiveness model”, which was constructed originally for similar 
study in UK, was modified and used for this analysis, while imputed data were 
replaced with Japanese data, as far as possible. Various health states, such as non-
cirrhotic hepatitis, sustained virological response (SVR), compensated cirrhosis, 
decompensated cirrhosis and hepatocellular carcinoma were incorporated to the 
model. Analyses were conducted for 4 scenarios, classified by treatment history 
(naive/experienced) and eligibility for interferon. Peg-interferon alpha with ribavirin 
was set as a comparator for those who were eligible for interferon. No treatment 
was selected for those who were not eligible for interferon. Probability of SVR was 
derived from clinical trials conducted in Japan. Other transition probabilities and 
utility scores of each health state were obtained from published data in Japan. 
Cost data for interferon-alpha and ribavirin were derived from national drug tariff 
(2014). For sofosbuvir, average European price was adopted since it was not yet 
approved in Japan. Other cost data, such as costs related to health states, were 
mainly obtained from claim data, provided by JMDC (Japan Medical Data Center). 
Inc. Time-horizon was set to lifetime. Costs and outcomes were discounted with 2% 
per annum, according to Japanese guideline. Results: For interferon-unsuitable 
patients, sofosbuvir was dominant to no-treatment. Sofosbuvir would save overall 
costs for JPY990,000 (USD9,900, JPY100= USD1) and prolonged 6.20QALY for treat-
ment naive patients. It would save JPY 837,000 and prolonged 6.08QALY for treat-
ment experienced group, For interferon-suitable patients, sofosbuvir would increase 
overall costs for JPY3,270,000 and prolonged 2.23QALY for treatment-naives. It would 
increase JPY1,551,000 and prolonged 2.36QALY for treatment-experienced. ICER 
were JPY1,470,000 and JPY657,000 per QALY gained, respectively. ConClusions: 
Sofosbuvir was considered to be cost-effective for treatment of genotype-2 HCV 
patients in Japan.
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objeCtives: In recent years a number of infections caused by Clostridium difficile 
has been significantly increasing. In Poland oral metronidazole constitutes the ther-
apy of choice of non-severe infection and first-recurrence, while oral vancomycin 
is recommended to be given in case of severe disease and subsequent recurrences. 
Fidaxomicin is a novel treatment for Clostridium difficile infections (CDI). The aim 
of this study was to perform a cost-utility analysis of fidaxomicin for the treatment 
of severe CDI compared to vancomycin. Methods: A meta-analysis of two ran-
domized clinical trials phase III comparing oral fidaxomicin and oral vancomycin 
in CDI was conducted. A Markov model was used to determine the cost-utility of 
fidaxomicin in patients with severe CDI. The cycle length was 10 days and the time 
horizon was 1 year. The patient entered the model in the severe CDI health state 
and was given either fidaxomycin or vancomycin for 10 days. The analysis was 
performed from the third-party payer perspective – the Polish National Health Fund. 
Only direct health care costs (drug costs, hospitalization) were included. Given the 
lack of formal utility measures for CDI, the utilities for the alternative health states 
described in the literature were adapted. Results: In the base case, fidaxomicin 
was dominant compared to vancomycin, resulting in cost savings of PLN 905 and 
an incremental QALY gain of 0.015. Fidaxomicin was associated with higher cost 
savings (PLN 30,883) assuming that patients with severe CDI would be hospital-
ized at intensive care unit. One-way sensitivity analyses revealed that fidaxomicin 
remained dominant even if considering marginal values of both antibiotics’ acqui-
sition cost. ConClusions: Fidaxomicin was dominant compared to vancomycin, 
generating additional QALYs with cost-savings in severe CDI patients in Poland.
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a systEmatIC rEvIEW
Haddad L.1, Decimoni T.2, Turri A.1, Leandro R.2, Soarez P.2
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objeCtives: The aim of this study was to systematically review the economic 
assessment studies carried out in Brazil, published between January 1980 and 
December 2013, assessing the technologies studied, study types, the and tem-
poral evolution and quality. Methods: We systematically searched in MEDLINE 
(PubMed), EMBASE, LILACS, SciELO, NHS EED, HTA Database (CRD), BVS ECOS, 
SCOPUS, Web of Science, and SISREBRATS. We selected partial and full economic 
evaluation studies in gastroenterology, where at least one of the authors was affili-
ated to a Brazilian institution. Two authors performed study selection and data 
extraction independently. Disagreements were resolved through discussion or 
through consultation with a third reviewer. The study characteristics were sum-
marized in figures and summary tables. Results: Forty studies were included. The 
first studies were published in the 80s, but most occurred after 2000, with greater 
frequency in the last 4 years. Seventeen economic evaluations were incomplete 
(42.5%) and 23 complete (57.5%). In the 23 complete reviews, 11 (47.8%) studies 
were cost-utility analysis, 7 (30.4%) were cost-effectiveness analysis, 4 (17.4%) cost-
consequence analysis, and 1 (4.3%) cost-minimization analysis. The type of technol-
ogy evaluated was mainly medications in 25 studies (62.5%), 7 (17.5%) medical and 
surgical procedures, 3 (7.5%) medical and hospital equipment, 1 (2.5%) vaccines and 
4 (10%) evaluated more than one type of technology. When classified by disease, 22 
(55%) were studies on viral hepatitis, and in its most published after the year 2010 
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on HRQoL of the general population is still lacking. The aim of our study was to 
fill this GAP. Methods: A dataset with HRQoL data of a representative sample 
of the general population of most populated Italian region was matched with the 
dataset from a multicenter study conducted in the same region and time period 
to generate and validate a set of health care outcomes indicators for the major 
LDs (hepatitis B (HBV), hepatitis C (HCV), compensated cirrhosis (CC), decom-
pensated cirrhosis (DC), hepatocellular carcinoma (HCC), autoimmune hepatitis 
(AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), NAFLD/
NASH and patients listed for liver transplant (LTL)). Within both datasets, HRQoL 
data were collected using the EQ-5D-3L. Multivariate logistic and Tobit regres-
sions were then performed adjusting for possible confounders (age, sex, education 
and working status). Results: A total of 6,800 “healthy subjects” and 3,105 sub-
jects with LDs were included in the analyses. Multivariate logistic analyses showed 
that DC, HCC, and LTL had significantly (p< 0.05) higher risk to have problems in 
mobility, self-care, and usual activities compared to “healthy subjects”. AIH had 
significantly higher risk to have problems in self-care; while HCV, CC, DC, and 
NAFLD/NASH in Anxiety/depression. Similar results were obtained with the Tobit 
model performed using VAS and Utility-index. DC, HCC, AIH and LTL reported 
the highest decrease in VAS and Utility score. ConClusions: HRQoL decreased 
in advanced LDs (DC, HCC, LTL) and AIH. This study provides an actual true esti-
mate of the impact of major LDs on the patients’ HRQoL compare to the general 
population, and therefore is a key tool for decision-making in care delivery for 
liver diseases.
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transLatIon anD CULtUraL aDaPtatIon DIffICULtIEs EnCoUntErED 
DUrInG LInGUIstIC vaLIDatIon of thE BrIstoL stooL sCaLE
Edwards A., Williams H., Anderson H.
ICON plc, Oxford, UK
objeCtives: The aims of this study were: (1) to investigate translation difficulties 
encountered during linguistic validation of the Bristol Stool Scale; (2) to discover 
whether certain items consistently posed problems across different languages; 
and (3) to analyse how solutions were reached and what types of solutions were 
appropriate. Methods: The investigation was made up of the following stages: 
(1) collation of back translation reviews of the Bristol Stool Scale for 30 European 
and Asia-Pacific languages; (2) identification of problematic words and phrases, 
based on written discussion between lead translators and project managers; (3) 
investigation of patterns that became apparent across different languages; (4) 
review of methods used to overcome the translation difficulties. Results: For 
more than a third of the languages reviewed (2 European and 9 Asia-Pacific, includ-
ing 7 Indian), difficulties were experienced when attempting to translate certain 
items word-for-word. The majority of these difficulties centred on the food-related 
similes used in the scale to describe the different stool types. In all of the Indian 
languages in this study, alternative food-related similes were deemed necessary 
(e. g. ‘banana’ replacing ‘sausage’) in order to ensure that the wording was cultur-
ally relevant. Of the other languages, Thai and Romanian preferred similes that 
did not relate to food (‘bullets’ and ‘beads/little round bits’ respectively, instead of 
‘nuts’), while for Singapore Chinese and Polish it was decided to remove certain 
similes altogether (‘like nuts’/‘like a sausage’). ConClusions: Certain items in 
the Bristol Stool Scale, in particular the two food-related similes, cause transla-
tion difficulties for some languages. For such items, it may not be appropriate to 
produce a word-for-word translation. In these cases, alternative solutions must 
be sought, taking into account cultural considerations, in order to achieve con-
ceptual equivalence.
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objeCtives: To describe and compare self-reported health-related quality of 
life (HRQL) in HCV Genotype-1 infected patients with and without comorbid 
conditions (e. g. depression, hypertension, obesity, arthritis, anemia and dia-
betes). Methods: A Cross-sectional survey of physicians and their consulting 
patients was conducted from October 2012 to January 2013 as part of the Adelphi 
Real World Hepatitis C Disease Specific Programme. Overall, 348 patients from USA 
and France (231 with comorbidities and 117 without comorbidities) completed an 
EQ5D-3L and/or a Multidimensional-Assessment-of-Fatigue (MAF) scale. HRQL was 
evaluated by estimating EQ5D health-state-index (EQ5D-HSI), Visual-Analogue-
Scale (EQ5D-VAS) score, Domain-dimension score and MAF Global-Fatigue-Index 
(MAF-GFI). Further analysis compared HRQL reported by patients with comorbidi-
ties who completed treatment for HCV and were cured versus those who were 
not cured. Results: HRQL reported by untreated patients were better for those 
without comorbidities than those with comorbidities. For three of the five EQ5D 
domains, more patients without comorbidities versus patients with comorbidities 
reported no problems performing usual activities (85% versus 49%, p< 0.001), no 
pain or discomfort (70% versus 33%, p< 0.001) and not being anxious/depressed 
(67% versus 37%, p= 0.004). The corresponding mean HQRL estimates were EQ5D-
HSI 0.89 vs 0.77, p= 0.001; EQ5D-VAS 79 vs. 69, p= 0.014 and MAF-GFI 11 vs. 19, 
p= 0.016 for patients without comorbidities versus those with comorbidities. 
Among treated patients with comorbidities, those cured had significantly higher 
HRQL than those not cured (EQ5D-HSI 0.84 versus 0.67, p= 0.008, EQ5D-VAS 74 
vs. 57, p= 0.003 and MAF-GFI 18 versus 32, p< 0.001). ConClusions: The results 
from this study suggest that patients with comorbidities have a poorer HRQL than 
patients without comorbidities, and that the treatment and cure of HCV in these 
patients is associated with higher HRQL compared with treatment and no cure. 
This implies that treatment and subsequent cure of HCV genotype 1 patients with 
comorbidities may help improve their HRQL.
caregivers. Results: 468 children and caregivers were included in this study. Mean 
children’s age was 1.77 years. The caregivers rated the mean child’s utility and 
themselves as 0.604 (95%CI: 0.592, 0.615) and 0.618 (95%CI: 0.606, 0.629), respectively. 
Mainly domains of diarrheal children were affected as pain/discomfort and anxiety/
depression similarly to their caregivers. On multivariate regression analysis, factors 
which affected the children’s utility significantly were Vesikari score, child’s age and 
child’s gender. Next, reduced QoL of their caregivers related to caregiver’s gender and 
Vesikari score. ConClusions: Diarrhea had an impact on quality of life of children 
and their caregivers. It appeared that QoL of children with diarrhea was impacted 
worse in girls, those with high severity score and was associated with age. In addi-
tion, the diarrheal severity and female gender reduced the impact of diarrhea on 
QoL of caregivers. These results can be useful to evaluate the cost-effectiveness of 
vaccines against diarrhea such as rotavirus vaccines.
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objeCtives: Little is known about the impact of OIC and treatments for OIC on 
health state utility. Studies often focus on collecting data on changes in OIC status. 
The objective of this paper is to examine if the utility impact of treatment is driven 
by change in OIC status, and what the magnitude of the change in utility associ-
ated with changes in OIC status is. Methods: 1352 patients with non-malignant 
OIC were allocated to one of two, phase III, 12 week randomised controlled trials 
to study naloxegol. These trials were pooled and prospective analyses on these 
data were undertaken. Both trials collected the three level EQ-5D at baseline, 
week 4 and week 12. EQ-5D scores were converted into estimates of utility using a 
tariff generated based on UK general population preferences. A repeated measure 
mixed model (RMMM) regression analysis was conducted to identify the impact 
of the following factors on utility: age, gender, race, BMI, duration of opioid use, 
treatment (naloxegol 12.5mg, 25mg or placebo), baseline utility and OIC status (OIC 
or non-OIC). Results: Baseline utility across all patients was 0.559. The regres-
sion demonstrated that baseline utility score (β = -0.532, SE= 0.023) and OIC status 
(β = 0.032, SE= 0.012) were the only significant predictors of change in utility score 
(p< 0.0001and p= 0.008 respectively). Further univariate analyses examined the 
effect of OIC status in patient subgroups that had different experiences of laxative 
treatment. OIC status had an increased and meaningful impact on patients who 
had previously responded inadequately to laxatives. ConClusions: OIC status 
is a significant factor on the impact of treatment on patient’s utility. Furthermore 
the impact of OIC status is increased in patients who had previously responded 
inadequately to laxatives.
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objeCtives: A recent double-blind, placebo-controlled clinical study with lubipros-
tone in opioid-induced constipation (OIC), OBD-1033, included the EQ-5D generic 
quality-of-life instrument, and the PAC-QOL, a constipation-specific disease meas-
ure. This study calculated utility values for patients with OIC using the direct EQ-5D 
responses, and compared the resulting utilities to those calculated from a published 
mapping formula between the PAC-QOL and EQ-5D that was derived in chronic idi-
opathic constipation. Methods: EQ-5D responses from OBD-1033 were converted 
to utilities using the EQ-5D UK value set. These were compared with utilities gener-
ated with the published mapping algorithm. Following this step, an attempt was 
made to map the PAC-QOL to the EQ-5D in OIC. The root mean squared error (RMSE), 
adjusted R2, and predicted/observed plots were used to assess the quality of map-
pings. Results: Patients in OBD-1033 had low utility values at baseline: mean= 0.45 
(Standard Deviation 0.33, n= 439). Using the published algorithm, the predicted mean 
utility was much higher: 0.74. This led to a high RMSE (0.43), indicating a poor fit 
to the data. Replicating the mapping using OBD-1033 PAC-QOL and EQ-5D data 
showed the PAC-QOL, although correlated with the EQ-5D, had a poor predictive 
value (RMSE= 0.31; R2< 0.10). High utilities were underestimated and low utilities 
overestimated. ConClusions: Mapping algorithms are a vital tool for generating 
utility values when none are available. However, the relationship derived between 
instruments should be assessed cautiously. Mappings with the same instruments 
may not be reliable if crossing disease areas – even if the symptoms experienced 
by patients appear similar. Data show patients in OBD-1033 entered the study with 
poorer health status than those in the chronic constipation mapping (utility of 
0.45 vs 0.81), likely due to comorbid conditions (the reason for opioid prescribing). 
This led to a different relationship between the PAC-QOL and EQ-5D, compared to 
the previous estimate.
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objeCtives: The impact of liver diseases (LDs) on health-related quality of life 
(HRQoL) is an important aspect to understand the burden of these conditions 
and improve their management. A well characterized impact of the major LDs 
